Suchergebnisse - "Penel, Nicolas"

PubPharm (18)

1

Regorafenib in patients with advanced Ewing sarcoma : results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

enthalten in: British journal of cancer | 2023

von Duffaud, F. | Blay, J. | Le Cesne, A. | +17

2

Regorafenib for the Treatment of Sarcoma

enthalten in: Current treatment options in oncology | 2022

von Blay, J. | Duffaud, F. | George, S. | +2

3

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma : Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Duffaud, F. | Italiano, A. | Bompas, E. | +21

CommentIn: Eur J Cancer. 2021 Nov;157:525-526. - PMID 34509345

4

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Penel, N. | Mir, O. | Wallet, J. | +17

5

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma : a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

enthalten in: The Lancet. Oncology | 2019

von Duffaud, F. | Mir, O. | Boudou-Rouquette, P. | +17

CommentIn: Lancet Oncol. 2019 Jan;20(1):12-14. - PMID 30477938

6

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Brodowicz, T. | Mir, O. | Wallet, J. | +13

7

Advanced chordoma treated by first-line molecular targeted therapies : Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Lebellec, L. | Chauffert, B. | Blay, J. | +16

8

REGOSARC : Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis

enthalten in: Cancer | 2017

von Berry, V. | Basson, L. | Bogart, E. | +14

CommentIn: Cancer. 2017 Jun 15;123(12):2200-2202. - PMID 28294292

9

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC) : a randomised, double-blind, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2016

von Mir, O. | Brodowicz, T. | Italiano, A. | +27

CommentIn: Lancet Oncol. 2016 Dec;17 (12 ):1633-1634. - PMID 27751848

10

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib : an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

enthalten in: Oncotarget | 2016

von Lebellec, L. | Bertucci, F. | Tresch-Bruneel, E. | +10